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Abstract
Background: Suppressors of cytokine signaling (SOCS) are important negative feedback regulators of the JAK/STAT 
signaling pathway, and have been recently investigated for their role in the development of different cancers. In this 
study, we examined the expression of SOCS1-7 genes in normal and breast cancer tissue and correlated this with 
several clinico-pathological and prognostic factors.
Methods: SOCS1-7 mRNA extraction and reverse transcription were performed on fresh frozen breast cancer tissue 
samples (n = 127) and normal background breast tissue (n = 31). Transcript levels of expression were determined using 
real-time PCR and analyzed against TNM stage, tumour grade and clinical outcome over a 10 year follow-up period.
Results: SOCS1,4,5,6 and 7 expression decreased with increased TNM stage (TNM1 vs. TNM3 p = 0.039, TNM1 vs. TNM4 
p = 0.016, TNM2 vs. TNM4 p = 0.025, TNM1 vs. TNM3 p = 0.012, and TNM1 vs. TNM3 p = 0.044 respectively). SOCS2 and 
3 expression decreased with increased Nottingham Prognostic Index (NPI) (NPI1 vs. NPI3 p = 0.033, and NPI2 vs. NPI3 p 
= 0.041 respectively). SOCS7 expression decreased with higher tumour grade (Grade 3 vs. Grade 2 p = 0.037). After a 
median follow up period of 10 years, we found higher levels of SOCS1,2 and 7 expression among those patients who 
remained disease-free compared to those who developed local recurrence (p = 0.0073, p = 0.021, and p = 0.039 
respectively). Similarly, we found higher levels of SOCS 2,4, and 7 expression in those who remained disease-free 
compared to those who developed distant recurrence (p = 0.022, p = 0.024, and p = 0.033 respectively). Patients who 
remained disease-free had higher levels of SOCS1 and 2 expression compared to those who died from breast cancer (p 
= 0.02 and p = 0.033 respectively). The disease free survival (DFS) and overall survival (OS) curves showed that higher 
levels of SOCS1, 3 and 7 were significant predictors of higher DFS (p = 0.015, p = 0.024 and 0.03 respectively) and OS (p 
= 0.005, p = 0.013 and p = 0.035 respectively). Higher levels of SOCS 4 were significant in predicting better OS (p = 
0.007) but not DFS. Immunohistochemical staining of representative samples showed a correlation between SOCS1, 3, 
7 protein staining and the SOCS1, 3, 7 mRNA expression.
Conclusion: Higher mRNA expression levels of SOCS1, 3, 4 and 7 are significantly associated with earlier tumour stage 
and better clinical outcome in human breast cancer.
Background
Signal transducers and activators of transcription
(STATs) are intra-cytoplasmic proteins which are acti-
vated by phosphorylation to participate in gene control
on a single tyrosine when cells encounter various extra-
cellular cytokines, growth factors and hormones [1-3].
Seven STAT proteins have been identified to date;
STAT1, 2, 3, 4, 5A, 5B, and 6 [1]. STAT binding to the
Janus Kinase (JAK) receptor-associated tyrosine kinases
occurs through the STAT SRC-homolgy-2 (SH2) domain
resulting in their subsequent dimerization, phosphoryla-
tion and activation. Phospho-STATs (pSTATs) then move
into the nucleus to be involved in the complex mecha-
nism of signal transduction which leads to transcription
of specific proteins. STAT3 plays a pleomorphic role in
signal transduction. It typically acts as an oncogene.
STAT3 regulates expression of VEGF and is associated
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Page 2 of 13with angiogenesis and tumor progression[4]. Activation
of STATs has been reported in many cancers; head and
neck, breast, prostate, pancreas and leukemia[5-10]. Fur-
thermore, STAT3 expression is reported to be correlated
with lymph node metastasis [11-13], and higher expres-
sion of STAT3 and pSTAT3 indicates a worse prognosis
[10,14-16]. More recent data have shown a controversial
role of STATs in breast cancer. Walker et al have demon-
strated that STAT5 and STAT3 mediate opposing effects
on several key target genes, with STAT5 exerting a domi-
nant role. Using a model system of paired breast cancer
cell lines, they found that co-activation of STAT5 and
STAT3 leads to decreased proliferation and increased
sensitivity to the chemotherapeutic drugs paclitaxel and
vinorelbine compared with cells that have only STAT3
activation [17].
The activation of the JAK/STAT pathway is negatively
regulated by a classical feedback loop through a group of
proteins named Suppressors of cytokine signaling
(SOCS) which are rapidly induced by activated STATs
[18]. SOCS family consists of 8 proteins (SOCS1-7 and a
cytokine-inducible SH2-containing protein or CIS), each
has a central SH2 domain, an amino-terminal domain of
variable length and sequence, and a carboxy-terminal 40-
amino-acid molecule known as the SOCS box. SOCS
molecules act to block the cytokine signal either by direct
inhibition of JAKs (e.g. SOCS1), or by binding to the
tyrosine-phosphorylated receptor to prevent binding of
other SH2 and PTB domain-containing signaling proteins
such as STATs (e.g. CIS), or by both mechanisms (e.g.
SOCS3) [19].
SOCS proteins (e.g. CIS) are also involved in a fourth
inhibitory mechanism which is their ability to accelerate
proteasome-mediated destruction of the activated
cytokine-receptor complex [19,20]. These inhibitory reg-
ulators not only attenuate the signal from the activated
cytokine receptor itself, but can also decrease cell sensi-
tivity to other cytokines and hormones, such as PGE2,
insulin, and prolactin [21-23].
Furthermore, other reports showed a role for the SOCS
proteins in regulating other signal transduction mole-
cules (e.g. FAK, IRS, p65, GR) that are highly relevant to
carcinogenesis [24-28]
Few studies have reported the role of SOCS proteins in
breast carcinoma, and their possible influence on tumour
growth and differentiation, but the general trend of their
results indicates a favorable role of SOCS in attenuating
cytokine signaling implicated in breast cancer growth.
Knowing that SOCS gene promoter hypermethylation is
an important mechanism in SOCS gene silencing and
subsequent deregulation of the JAK/STAT signaling,
Sutherland et al found promoter hypermethylation and
silencing of SOCS1 (but not of SOCS2 or SOCS3) to
occur in 9% of breast cancers and various degrees of
SOCS transcription in several breast carcinoma cell lines,
and suggested that silencing of specific SOCS genes in
breast, may augment cytokine responsiveness, thereby
contributing to oncogenesis [29]. Another report by Fara-
begoli et al demonstrated that SOCS2 expression was
associated with high differentiation and a low prolifera-
tion rate in a group of 50 archival breast cancer samples,
and was found to inversely correlate with several prolifer-
ation markers such as cyclin A and Ki-67 [30]. Haffner et
al found an inverse correlation between SOCS2 mRNA
expression and histopathological grade, and ER positive
tumours exhibited higher SOCS 2 levels [31]. The later
study has also reported SOCS2 as a significant indepen-
dent predictor of good prognosis. A further study by
Nakagawa et al has proved a lower SOCS1 and 3 expres-
sion in specimens with blood vessel invasion and in sam-
ples from patients with lymph node positive disease with
the lowest SOCS3 expression found in patients with more
than 4 lymph nodes involved in the metastatic process
[32].
In view of this potential importance of SOCS expres-
sion in regulation of growth and development of breast
cancer, and in view of the favorable data from previous
reports, we have examined the expression of SOCS1-7 in
a group of archival normal and breast cancer tissue speci-
mens, and correlated their expression levels with several
clinical, pathological and prognostic parameters within
the same cohort of patients.
Methods
Patients and samples
Institutional guidelines, including informed consent,
were followed. Ethical approval was obtained from St
George's Healthcare NHS Trust ethics committee. Pri-
mary breast cancer tissues (n = 127) and matched non-
neoplastic mammary tissue (from the same mastectomy
specimens) (n = 31) were collected immediately after sur-
gical excision and stored at -80°C for future use. Details of
histology were provided by independent specialist
pathologist using hematoxylin and eosin (H & E) - frozen
sections. Where normal non-neoplastic tissues were
used, no tumour cells were found in the sections. All tis-
sues were randomly numbered and the details were only
made known after all analyses were completed. All
patients were treated according to local algorithms of
management following a multidisciplinary discussion.
Patients treated with breast-conserving surgery received
adjuvant radiotherapy. Those with hormone- sensitive
malignancy received tamoxifen. Fit patients with node-
positive breast cancer or hormone-insensitive large and/
or high grade cancer were offered adjuvant chemother-
apy. Medical notes and histology reports were used to
extract clinico-pathological data (Table 1).
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RNA extraction kits and reverse transcription kits were
obtained from Sigma-Aldrich Ltd (Poole, Dorset, Eng-
land, UK). The PCR primers were designed using Beacon
Designer (Palo Alto, CA, USA) and synthesized by
Sigma-Aldrich. Custom made hot-start Master mix for
quantitative Polymerase Chain Reaction (PCR) was
obtained from Abgene (Surrey, England, UK) [33,34].
Tissue processing, RNA extraction and cDNA synthesis
Frozen sections of tissue were cut at a thickness of 5 - 10
μm and kept for routine histological analysis. Additional
15-20 sections were mixed and homogenized using a
hand-held homogenizer in ice-cold RNA extraction solu-
tion. The concentration of RNA was determined using
UV spectrophotometry. Reverse transcription was car-
ried out using a reverse transcription kit with an
anchored oligo (dT) primer supplied by Abgene, using 1
μg of total RNA in a 96-well plate. The quality of cDNA
was verified using β-actin primers (Table 2).
Immnunohistochemical staining for frozen sections
The SOCS3 protein was detected by a rabbit polyclonal
antibody (H-103; Santa Cruz Biotechnology Inc, Santa
Cruz, California, USA). For SOCS7 protein detection,
goat polyclonal antibody was used (C-19; Santa Cruz Bio-
technology Inc, Santa Cruz, California, USA). The proce-
dure was similar to that previously reported, with minor
modifications[34,35]. Briefly, the frozen sections of breast
tumour and non-neoplastic breast tissue were cut at a
thickness of 5 μm using a cryostat. The sections were
mounted on microscope slides, air-dried and then fixed
in a mixture of 50% acetone and 50% methanol for 20
min. The sections were then placed in a Menapath
autowash buffer for 5-10 min to rehydrate. Sections were
incubated for 20 min in a horse serum blocking solution
and probed with the primary antibody (1:50 dilution
Anti-SOCS3, and Anti-SOCS7) at room temperature for
1 h. Following extensive washings, sections were incu-
bated for 30 min in the secondary horse serum. Following
washings, Avidin biotin complex (Vector Laboratories
Ltd.) was then applied to the sections, followed by exten-
sive washings. Diaminobenzidine chromogen (Vector
Table 1: Clinical and pathological data (follow up period 120 +/- 6 months)
Parameter Category Number
Node status Node positive 54
Node negative 73
Tumour grade 1 24
2 43
3 58
Tumour type Ductal 98
Lobular 14
Medullary 2
Tubular 2
Mucinous 4
Others 7
TNM staging 1 70
2 40
3 7
4 4
Outcome Disease free 90
Alive with metastasis 7
With local recurrence 5
Died of breast cancer 16
Died of unrelated disease 9
Note: missing values reflect discarded/uninterpretable values.
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were incubated in the dark for 5 min. The sections were
then dehydrated in ascending grades of methanol before
clearing in xylene and mounting under a coverslip before
initial photographs were taken. A rehydration process
was then performed with descending grades of methanol
before removing the coverslip and counterstaining in
Mayer's hematoxylin for 1 min.
The process of dehydration and mounting was then
repeated. Staining intensity was semiquantified using a
method established in our laboratory [34], which was
modified and based on that reported by Fidler and col-
leagues[35]. Briefly, gray-scale digitized images were
imported into the Optimas software (Optimas 6.0, Opti-
mus Corp., Bothell, WA, USA). Control staining (without
primary antibody) was used for the extraction of the
background staining.
Quantitative analysis
The level of SOCS1 - 7 transcripts from the above pre-
pared DNA were determined using real-time quantitative
PCR based on the Amplifluor technology, modified from
a method reported previously [32]. The PCR primers
were designed using Beacon Designer software, but an
additional sequence, known as the Z sequence (5'-ACT-
GAACCTGACCGTACA-3') which is complementary to
the universal Z probe (Intergen Inc., Oxford, UK) was
added to the reverse primer. The primers used for each
SOCS are detailed in table 2. The reaction was carried
out using Hotstart Q-master mix (Abgene), 10 pmol of
the specific forward primer, 1 pmol of reverse primer
which had the Z sequence, 10 pmol of FAM- tagged
probe (Intergen Inc.), and cDNA from 50 ng of RNA. The
reaction was carried out using the IcyclerIQ (Bio-Rad
Ltd, Hemel Hempstead, England, UK), which is equipped
with an optic unit that allows real-time detection of 96
reactions, under the following conditions: 94°C for 12
min and 50 cycles of 94°C for 15 sec, 55°C for 40 sec, and
72°C for 20 sec. The levels of the transcript were gener-
ated from a standard plasmid contained the specific DNA
sequence that was simultaneously amplified with the
samples. The levels of SOCS1-7 gene expression were
then normalized against the housekeeping gene β-actin,
which was already quantified in these specimens. Abso-
lute quantification analysis was used and the resulting
expression data were presented as ratios to β-actin [36].
The primers used for β-actin are detailed in table 2. With
every PCR run, a negative control without a template and
a positive control known cDNA reference sample, were
included.
Statistical analysis
The Mann-Whitney U-test (comparison of median copy
number) and two-sample t-test (comparison of mean
copy number) were used for statistical analysis of abso-
lute and normalised gene copy number. The transcript
levels within the breast cancer specimens were compared
to normal background tissues and analyzed against con-
ventional pathological parameters and clinical outcome
over a 10 year follow-up period.
Within the tumour samples, the correlation between
SOCS1 - 7 and downstream regulated genes was exam-
Table 2: SOCS1 - 7 Primers
SOCS1
Forward GATGGTAGCACACAACCAG
Z Reverse ACTGAACCTGACCGTACAGAGGAAGAGGA
GGAAGGTT
SOCS2
Forward GGATGGTACTGGGGAAGTAT
Z Reverse ACTGAACCTGACCGTACATGCGAGCTATCT
CTAATCAA
SOCS3
Forward CCACTCTTCAGCATCTCTGT
Z Reverse ACTGAACCTGACCGTACAATCGTACTGGTC
CAGGAACT
SOCS4
Forward GGCAGTGTTTTCCAATAAAG
Z Reverse ACTGAACCTGACCGTACAAGGTGGGAAAG
GACACTTAT
SOCS5
Forward AGTCAAAGCCTCTCTTTTCC
Z Reverse ACTGAACCTGACCGTACACATTTTTGGGCTA
AATCTGA
SOCS6
Forward CCTTACAGAGGAGCTGAAAA
Z Reverse ACTGAACCTGACCGTACACGAACAAGAAAA
GAACCATC
SOCS7
Forward CAGGCCCTGAATTACCTC
Z Reverse ACTGAACCTGACCGTACAGAGGTTGCTGCT
GCTGCT
β-Actin
Forward ATGATATCGCCGCGCTCGTC
Reverse CGCTCGGTGAGGATCTTCA
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the true copy number was used for statistical analysis and
hence the samples were not classified as positive or nega-
tive. The statistical analysis was carried out using Minitab
version 14.1 (Minitab Ltd. Coventry, England, U.K.) using
a custom written macro (Stat 2005.mtw).
For purposes of the Kaplan-Meier survival analysis, the
samples were divided arbitrarily into two groups, 'high
transcript level' or 'low transcript level', for each SOCS
gene. The cut-off was guided by the Nottingham Prog-
nostic Index (NPI) value, with which the value of the
moderate prognostic group was used as the dividing line
at the start of the test. Disease Free Survival (DFS) and
Overall Survival (OS) analyses were performed using
SPSS version 12.0.1 (SPSS Inc. Chicago, IL, USA). For
multivariate analysis using the Cox regression model,
PASW Statistics 18 Software (Chicago, IL, USA) was
used.
Results
SOCS1 - 7 mRNA expression by Quantitative PCR
The SOCS1-7 expression profiles were determined both
in absolute terms and normalised against β-actin. All
SOCS1-7 expression profiles showed no significant dif-
ferences in association with different responses to che-
motherapy in the patient cohort.
SOCS1 (Table 3)
SOCS1 was found to be expressed in both normal/benign
breast tissue and breast cancer specimens. No significant
difference was found between SOCS1 expression in
breast cancer specimens and its expression in normal
background tissue.
The expression of SOCS1 mRNA did not significantly
differ with increasing Nottingham Prognostic Index
(NPI) or between normal background breast tissue and
tumour tissues of patients with different NPI levels. The
expression of SOCS1 mRNA was demonstrated to signif-
icantly decrease with increasing TNM stage; TNM-1 vs.
TNM-3 [mean copy number 53 vs. 5.7, 95% CI (2, 91.5), p
= 0.039], and TNM-1 vs. TNM-4 [mean copy number 53
vs. 3.2, 95% CI (6, 93.3), p = 0.027].
Transcript levels did not significantly differ with differ-
ent tumour grades or with oestrogen receptor (ER) status.
After a median follow up of 10 years, we found SOCS1
mRNA expression levels to be higher among women who
remained disease free compared to those who developed
local recurrence [mean copy number 48 vs. 1.2, 95% CI
(13, 81.2), p = 0.0073], and compared to those who died
from breast cancer [mean copy number 48 vs. 7.4, 95% CI
(6, 75.6), p = 0.021].
SOCS1 expression was also higher among patients who
remained disease free compared to all other patients who
developed any type of recurrence (local or distant) or
died from breast cancer during the same follow up period
[mean copy number 48 vs. 4.3, 95% CI (10, 78.2), p =
0.012].
There was a trend for tumours with lower SOCS1
expression levels to be associated with shorter DFS and
OS times. The DFS and OS curves for women with
tumours which were classified as having 'high levels' of
SOCS1 transcripts were found to differ significantly from
those of their 'low level' counterparts. The survival curves
show higher levels of SOCS1 were of significant benefit in
predicting higher DFS (p = 0.015) and better OS (p =
0.005). (Figures 1 and 2)
SOCS2 (Table 3)
SOCS2 was found to be expressed in both normal/benign
breast tissue and breast cancer specimens. No Signifi-
cantly different levels were found in breast cancer speci-
mens compared to normal background tissue. The
expression of SOCS2 mRNA was found to decrease with
increasing NPI; NPI-1 vs. NPI-3 [mean copy number
495133 vs. 12414, 95% CI (39141, 926297), p = 0.033], but
was found to significantly increase with higher tumour
grade; grade 2 vs. grade 3 [mean copy number 44859 vs.
512760, 95% CI (-921508, -14293), p = 0.043]. SOCS2
transcript levels were not significantly different with ER
status.
After a median follow up of 10 years, we found SOCS2
mRNA expression levels to be higher among women who
remained disease free compared to those who developed
local recurrence [mean copy number 360706 vs. 3499,
95% CI (54131, 660284), p = 0.021], compared to those
who developed distant recurrence [mean copy number
360706 vs. 3897, 95% CI (53710, 659909), p = 0.022], and
compared to those who died from breast cancer [mean
copy number 360706 vs. 27239, 95% CI (27587, 639348),
p = 0.033]. SOCS2 expression was also higher among
those who remained disease free compared to all other
patients who developed any type of recurrence (local or
distant) or died from breast cancer during the same fol-
low up period [mean copy number 360706 vs. 16359, 95%
CI (40447, 648249), p = 0.027].
The DFS curve for women with tumours with 'high lev-
els' of SOCS2 transcript was not found to differ signifi-
cantly from that of their 'low level' counterparts.
Similarly, data from patients with tumours with higher
transcript levels showed no statistically significant associ-
ation with OS.
SOCS3 (Table 3)
There was neither a significant difference in SOCS3
mRNA expression levels between cancer tissue and nor-
mal background tissue nor there was a significant differ-
ence in the transcript levels with different tumour grades
or TNM classes. There was, however, a significantly
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NPI-3 [mean copy number 2.14 vs. 0.092, 95% CI (0.09,
4.003), p = 0.041]. The DFS curve for women with
tumours which were classified as having 'high levels' of
SOCS3 transcript was found to differ significantly from
that of their 'low level' counterparts, showing a significant
benefit in predicting better DFS (p = 0.024). Similarly, the
OS curve of patients with tumours classified as having
higher transcript levels predicted a better OS (p = 0.013).
(Figures 1 and 2)
SOCS4 (Table 4)
The expression of SOCS4 mRNA was demonstrated to
decrease with increasing TNM stage; TNM-1 vs. TNM-4
[mean copy number 384 vs. 1.51, 95% CI (73, 691.9), p =
0.016], and TNM-2 vs. TNM-4 [mean copy number 180
vs. 1.51, 95% CI (1, 355.5), p = 0.049] but did not signifi-
cantly differ with tumour grade or with NPI.
After a median follow up of 10 years, SOCS4 mRNA
expression levels were higher among women who
remained disease free compared to those who developed
distant recurrence [mean copy number 146 vs. 2.07, 95%
CI (19, 269.6), p = 0.024].
After a median follow up of 10 years, there was a trend
for tumours with higher SOCS4 expression levels to be
associated with better OS (p = 0.007), and with marginal
benefit in DFS although the later remained below statisti-
cal significance (p = 0.05). (Figures 1 and 2)
SOCS5 (Table 4)
SOCS5 levels of expression were significantly lower in
tumour tissue from patients with TNM-4 stage disease
Table 3: SOCS 1 - 3 Mean mRNA expression levels
Patient and tumour 
characteristics
SOCS1 Mean (SD) P SOCS2 Mean (SD) P SOCS3 Mean (SD) P
ER Status
ER(-) vs. ER(+) 47(165) vs. 18.4(38.4) 0.18 329585 (1361524) vs. 241896 (1097499) 0.72 0.6 (3.1) vs. 3.2 (10.7) 0.16
Tumor Grade
Grade 1 vs. 2 90(189) vs. 41(163) 0.33 335817 (1426927) vs. 44859 (128040) 0.37 4 (13.5) vs. 0.8 (4.1) 0.32
Grade 1 vs. 3 90(189) vs. 10.3(53.6) 0.08 335817 (1426927) vs. 512760 (1654661) 0.65 4 (13.5) vs. 0.7 (3.1) 0.3
Grade 2 vs. 3 41(163) vs. 10.3(53.6) 0.26 44859 (128040) vs. 512760 (1654661) 0.04 0.8(4.1) vs. 0.7 (3.1) 0.9
NPI
NPI 1 vs. 2 20.1(86.4) vs. 51(178) 0.32 495133 (1685902) vs. 66274 (241181) 0.06 1.2 (7.7) vs. 2.1 (6) 0.52
NPI 1 vs. 3 20.1(86.4) vs. 58(148) 0.35 495133 (1685902) vs. 12414 (25254) 0.03 1.2 (7.7) vs. 0.1 (0.2) 0.26
NPI 2 vs. 3 51(178) vs. 58(148) 0.88 66274 (241181) vs. 12414 (25254) 0.18 2.1 (6) vs. 0.1 (0.2) 0.04
TNM
TNM 1 vs. 2 53(170) vs. 20.5(67.1) 0.19 157325 (679157) vs. 364680 (1454925) 0.42 1.9 (8.4) vs. 0.9 (3.6) 0.79
TNM 1 vs. 3 53(170) vs. 5.7(13) 0.039 157325 (679157) vs. 1180151 (3122352) 0.42 1.9 (8.4) vs. 0.3 (0.9) 0.17
TNM 1 vs. 4 53(170) vs. 3.2(5.3) 0.027 157325 (679157) vs. 3256 (6508) 0.08 1.9 (8.4) vs. 0.2 (0.2) 0.12
TNM 2 vs. 3 20.5(67) vs. 5.7(13) 0.23 364680 (1454925) vs. 1180151 (3122352) 0.52 0.9 (3.6) vs. 0.3 (0.9) 0.39
TNM 2 vs. 4 20.5(67) vs. 3.2(5.3) 0.13 364680 (1454925) vs. 3256 (6508) 0.14 0.9(3.6) vs. 0.2 (0.2) 0.23
TNM 3 vs. 4 5.7(13) vs. 3.2(5.3) 0.67 1180151(3122352) vs. 3256 (6508) 0.36 0.3(0.9) vs. 0.2 (0.2) 0.68
Survival
DF vs. LR 48(154) vs. 1.2(3.2) 0.007 360706 (1370000) vs. 3499 (9061) 0.02 1.5 (7.3) vs. 0.8 (2.1) 0.55
DF vs. DR - - 360706 (1370000) vs. 3897(8714) 0.02 - -
DF vs. D 48(154) vs. 7.4(13.3) 0.02 360706 (1370000) vs. 27239 (81017) 0.03 1.5 (7.3) vs. 0.4 (1.1) 0.22
SOCS 1 - 3 Mean mRNA expression levels in a cohort of 128 breast cancer patients; a comparison between subgroups with different tumour grade, 
NPI score, and TNM stage. SD: Standard deviation, DF: Disease free survival, LR: Local disease recurrence, DR: Distant disease recurrence, D: Death 
from breast cancer
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ground tissue [mean copy number 0.263 vs. 4318, 95% CI
(-7867.49, -769), p = 0.019]. Similarly, SOCS5 mRNA
expression was found to significantly decrease with
increasing TNM stage; TNM-1 vs. TNM-4 [mean copy
number 1856 vs. 0.263, 95% CI (1063, 2648.36), p =
0.0000] and TNM-2 vs. TNM-4 [mean copy number 2328
vs. 0.263, 95% CI (315, 4340.62), p = 0.025]. No prediction
of better DFS or OS was found to be significantly associ-
ated with lower SOCS5 levels after 10 years follow up
period.
SOCS6 (Table 4)
SOC6 mRNA expression was found to significantly
decrease with increasing tumour TNM stage: TNM-1 vs.
TNM-3 [mean copy number 552 vs. 93, 95% CI (106,
812), p = 0.012]; and TNM-1 vs. TNM-4 [mean copy
number 552 vs. 22.8, 95% CI (216, 843), p = 0.0013]. DFS
and OS survival curves showed no significance of SOCS6
Figure 1 Kaplan Meier Disease Free Survival (DSF) Curves for SOCS1,3,4,7. Survival times are expressed as mean number of months with 95% 
confidence interval.
  
                                          Follow up (months)                                               Follow up (months) 
SOCS1:  Censored subjects: 14 in high expression group (n= 23)
and 59 in low expression group (n= 70). P= 0.015 
SOCS3:Censored subjects: 14 in high expression group (n= 21)
and 59 in low expression group (n= 72). P= 0.024 
                     
  
                                        Follow up (months)                                         Follow up (months) 
SOCS4:Censored subjects: 15 in high expression group (n= 24)
and 58 in low expression group (n= 69). P= 0.05 
SOCS7: Censored subjects: 30 in high expression group (n= 33)
and 43 in low expression group (n= 60). P= 0.03 
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years follow up period.
SOCS7 (Table 4)
SOCS7 was found to be expressed in both normal/benign
breast tissue and breast cancer specimens. No significant
difference was found between SOCS7 expression in nor-
mal background tissue and its expression in breast cancer
tissue.
The expression of SOCS7 mRNA did not significantly
differ with increasing Nottingham Prognostic Index
(NPI) or between normal background breast tissue and
tumour tissues of patients with different NPI levels, but
significantly decreased with increasing tumour grade;
grade 2 vs. grade 3 [mean copy number 1396 vs. 427, 95%
CI (62, 1876), p = 0.037].
The expression of SOCS7 mRNA was found to signifi-
cantly decrease with increasing TNM stage; TNM-1 vs.
TNM-3 [mean copy number 2239 vs. 137, 95% CI (56,
Figure 2 Kaplan Meier Overall Survival (OS) Curves for SOCS1,3,4,7. Survival times are expressed as mean number of months with 95% confi-
dence interval.
  
                                                Follow up (months)                                             Follow up (months) 
SOCS1: Censored subjects: 15 in high expression group (n= 23)
and 62 in low expression group (n= 70). P= 0.005 
SOCS3: Censored subjects: 15 in high expression group (n= 21)
and 62 in low expression group (n= 72). P= 0.013 
 
  
                                      Follow up (months)                                       Follow up (months)
SOCS4:Censored subjects: 15 in high expression group (n= 24)
and 62 in low expression group (n= 69). P= 0.007 
SOCS7: Censored subjects: 31 in high expression group (n= 33)
and 46 in low expression group (n= 60). P= 0.035 
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Table 4: SOCS 4 - 7 Mean mRNA expression levels
Patient and 
tumour 
characteristics
SOCS4 Mean (SD) P SOCS5 Mean (SD) P SOCS6 Mean (SD) P SOCS7 Mean (SD) P
ER Status
ER(-) vs. ER(+) 198 (834) vs. 296 (1035) 0.63 1669 (2950) vs. 1066 (2215) 0.25 450 (1209) vs. 2018 (5905) 0.13 2310 (8080) vs. 715 (1341) 0.11
Tumor Grade
Grade 1 vs. 2 142 (540) vs. 554 (1468) 0.13 834 (2468) vs. 2164 (3270) 0.09 2110 (7427) vs. 968 (2171) 0.51 5459 (14250) vs. 1396 (2583) 0.22
Grade 1 vs. 3 142 (540) vs. 113 (380) 0.82 834 (2468) vs. 2076 (5191) 0.17 2110 (7427) vs. 475 (1267) 0.34 5459 (14250) 0.13
Grade 2 vs. 3 554 (1468) vs. 113 (380) 0.07 2164 (3270) vs. 2076 (5191) 0.92 968 (2171) vs. 475 (1267) 0.21 vs. 427 (1339) 1396 (2583) vs. 427 (1339) 0.037
NPI
NPI 1 vs. 2 276 (1004) vs. 168 (513) 0.49 1742(2846) vs. 1715 (3064) 0.97 1117 (4564) vs. 687 (1610) 0.51 2740 (8754) vs. 518 (1189) 0.06
NPI 1 vs. 3 276 (1004) vs. 419 (1441) 0.72 1742 (2846) vs. 3132 (9006) 0.56 117 (4564) vs. 439 (1138) 0.31 2740 (8754) vs. 538 (1125) 0.07
NPI 2 vs. 3 168 (513) vs. 419 (1441) 0.52 1715 (3064) vs. 3132 ( 9006) 0.56 687 (1610) vs. 439 (1138) 0.53 518 (1189) vs. 538 (1125) 0.95
TNM
TNM 1 vs. 2 384 (1208) vs. 180 (532) 0.25 1856 (3095) vs. 2328 (6035) 0.66 552 (1217) vs. 1925 (5786) 0.16 2239 (7923) vs. 1329 (4566) 0.47
TNM 1 vs. 3 384(1208) vs. 75 (198) 0.08 1856 (3095) vs. 1521(3114) 0.8 552 (1217) vs. 93 (217) 0.01 2239 (7923) vs. 137 (353) 0.04
TNM 1 vs. 4 384 (1208) vs. 1.5 (3) 0.02 1856 (3095) vs. 0.26 (0.53) 0.00 552 (1217) vs. 156 (33.7) 0.001 2239 (7923) vs. 0.004 (0.008) 0.03
TNM 2 vs. 3 180 (532) vs. 75 (198) 0.37 2328 (6035) vs. 1521 (3114) 0.61 1925 (5786) vs. 93 (217) 0.06 1329 (4566) vs. 137 (353) 0.13
TNM 2 vs. 4 180 (532) vs. 1.5 (3) 0.049 2328 (6035) vs. 0.26( 0.53) 0.03 1925 (5786) vs. 22.8 (33.7) 0.05 1329 (4566) vs. 0.004 (0.008) 0.09
TNM 3 vs. 4 75 (198) vs. 1.5 (3) 0.36 1521 (3114) vs. 0.26 (0.53) 0.24 93 (217) vs. 22.8 (33.7) 0.43 137 (353) vs. 0.004 (0.008) 0.35
Survival
DF vs. LR 146 (566) vs. 959 (2223) 0.37 1551 (2851) vs. 1807 (2315) 0.79 994 (3987) vs. 776 (1311) 0.75 2110 (7490) vs. 271 (716) 0.04
DF vs. DR 146 (566) vs. 2.1 (3.3) 0.024 1551 (2851) vs. 10190 (14338) 0.25 994 (3987) vs. 372 (582) 0.23 2110 (7490) vs. 246 (500) 0.03
DF vs. D 146 (566) vs. 685 (1577) 0.23 1551 (2851) vs. 1190 (2787) 0.66 994 (3987) vs. 825 (1967) 0.81 2110 (7490) vs. 467 (1232) 0.07
SOCS 4 - 7 Mean mRNA expression levels in a cohort of 128 breast cancer patients; a comparison between subgroups with different tumour grade, NPI score, and TNM stage. SD: Standard deviation, 
DF: Disease free survival, LR: Local disease recurrence, DR: Distant disease recurrence, D: Death from breast cancer
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Page 10 of 134148), p = 0.044], and TNM-1 vs. TNM-4 [mean copy
number 2239 vs. 0.00375, 95% CI (209, 4268.3), p =
0.031].
SOCS7 transcript levels did not significantly differ with
different tumour grades or with ER status.
After a median follow up of 10 years, we found SOCS7
mRNA expression levels to be higher among women who
remained disease free compared to those who developed
local recurrence [mean copy number 2110 vs. 271, 95%
CI (99, 3580), p = 0.039]; and compared to those who
developed distant metastasis [mean copy number 2110
vs. 246, 95% CI (149, 3578), p = 0.033]. SOCS7 expression
was also higher among those who remained disease free
compared to all other patients who developed any type of
recurrence (local or distant) or died from breast cancer
during the same follow up period [mean copy number
2110 vs. 372, 95% CI (40, 3436), p = 0.045].
There was a trend for tumours with lower SOCS7
expression levels to be associated with shorter DFS and
OS times. The DFS and OS curves for women with
tumours which were classified as having 'high levels' of
SOCS7 transcript were found to differ significantly from
those of their 'low level' counterparts. (Figures 1 and 2)
The survival curves show that higher levels of SOCS7 are
significant in predicting higher DFS (p = 0.03) and better
OS (p = 0.035).
Multivariate Analysis using Cox regression model
Table 5 summarizes the p value for the prognostic signifi-
cance of the respective factors in predicting the overall
survival and disease free survival, using Multivariate
analysis based on the Cox regression model.
SOCS3 and SOCS7 protein expression by 
immunohistochemistry
In 8 samples of primary breast cancer, immunohis-
tochemical staining of SOCS3 and 7 correlated with their
respective mRNA expression. In tumours with high
SOCS3 and 7 mRNA expression levels, epithelial tumour
cells showed cytoplasmic staining for the respective
SOCS proteins (Figure 3). In normal mammary tissue,
ducts, and stroma; cells exhibited staining for SOCS3 and
7 (not shown).
Discussion
Several studies have investigated the role of SOCS pro-
tein family in the oncogenesis of several types of solid and
haematological tumours indicating an important role of
SOCS protein family in the tumour cellular growth and
differentiation [29,37-42]. One important mechanism is
SOCS gene promoter methylation which may result in
SOCS gene silencing and subsequent loss of negative
feedback control on the JAK/STAT signaling pathway in
tumour cells [29,38-42]. Conversely, demethylation of
SOCS genes promoters may result in restoration of SOCS
mRNA and proteins expression, which in turn results in
induction of apoptosis and suppression of growth [29].
Cytokine stimulation activates the JAK-STAT pathway,
leading to induction of SOCSs. These SOCS proteins
then inhibit the signaling pathways that STATs initially
Table 5: Prediction of overall survival and disease free survival, using multivariate analysis based on Cox regression 
model.
PREDECTIVE FACTORS OVERALL SURVIVAL (p) DISEASE FREE SURVIVAL (p)
NPI 0.675 0.435
Grade 0.96 0.92
TNM 0.667 0.252
Nodal 0.092 0.504
SOCS1 0.025 0.089
SOCS2 0.785 0.37
SOCS3 0.76 0.91
SOCS4 0.32 0.739
SOCS5 0.55 0.258
SOCS6 0.043 0.374
SOCS7 0.024 0.083
A Summary of the p values for the prognostic significance of the respective factors in predicting overall survival and disease free survival, 
using multivariate analysis based on Cox regression model.
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Page 11 of 13led to their production. SOCS proteins therefore act as
part of a negative feedback loop. In various cancers, inhi-
bition of STAT signaling - most significantly by SOCS
proteins - suppresses cancer cell growth and induces
apoptosis [29,43]. More data was particularly evident in
SOCS1 and SOCS3 roles as tumor suppressors. In gastric
cancer, for example, loss of SOCS 1 may be involved in
lymph node metastasis and tumor progression [37], while
restoration of its expression suppressed development and
progression of hepatocellular carcinoma cells [44]. Simi-
larly, SOCS3 may also be involved in the suppression of
tumour growth and metastasis of several malignancies
including lung cancer, hepatocellular cancer, and head
and neck squamous cell carcinoma [45-47]. More recent
studies showed that over-expression of SOCS3 markedly
suppressed STAT3 expression, and inhibited STAT5
phosphorylation, resulting in decreased cell proliferation
in T47D breast cancer cell lines, and decreased prolifera-
tion and anchorage-independent growth in MCF7 breast
cancer cell lines[21]. Furthermore, the relative decreasing
levels of SOCS expression in human breast tumours have
been previously quantified and It was suggested an
important local host defense mechanism during the pro-
gression period from in situ to invasive ductal carcinoma
characterized by intense cytokine production from the
lymphocytic infiltration. Such increased cytokine pro-
duction as a part of this local mechanism induces SOCS
protein over-expression [43]. Thus, a study by Camp et al
performed on 89 human breast carcinomas showed
strong lymphocytic production of Il-2, Il-4, TGF-β1,
TNF-α as well as lower levels of IFNγ and GM-CSF [44].
These cytokines are major activators of SOCS/CIS signal-
ling, particularly SOCS1 and 3 in granulocytes and lym-
phocytes [18,45].
In addition to the conventional inflammatory cytok-
ines, PRL and GH - the major mammotrophic hormones
- as well as IGF-I, may be involved in SOCS gene induc-
tion during breast carcinogenesis, and particularly known
to induce substantial SOCS1-3 and CIS gene expression
[23,46].
Therefore - and given the ubiquitous nature of SOCS
gene expression in response to host cytokines - it is not
unexpected that breast tumour tissue shows elevated
SOCS expression [30].
Such over-expression of SOCS genes is thought to be a
specific lesion in breast cancer tissue cells which may
provide resistance to pro-inflammatory and trophic
cytokines through blocking STAT signaling which medi-
ates essential functions in the mammary tissue, and may
well be implicated in mammary oncogenesis [47].
The above argument suggests a strong tumour sup-
pressing role of SOCS proteins. However, little informa-
tion exists regarding the significance of the association of
various SOCS proteins expression with prognosis and
clinico-pathological features of breast cancer.
In this study, we intended to elucidate the relationship
between various clinical, pathological, prognostic and
survival parameters and the expression of the SOCS fam-
ily proteins 1 - 7 in patients with breast cancer using RT-
PCR.
Our results show decreased SOCS 1,4,5,6 and 7 expres-
sion with increased TNM stage and decreased SOCS7
expression with higher tumour grade. These findings
together with results from previous studies on SOCS 2
expression in breast cancer [30,31], and the observations
from another report confirming higher expression levels
of SOCS3 in tissues from patients with lymph node nega-
tive breast cancer [32]; strongly suggest a highly signifi-
cant negative correlation between SOCS proteins and
advancing clinico-pathological stage and poorer differen-
tiation of breast carcinoma.
Furthermore, our results show decreased SOCS2 and 3
expressions with increased Nottingham Prognostic Index
(NPI) which adds significant positive prognostic role of
these proteins in breast cancer.
SOCSs mRNA expression (with the exception of
SOCS5) showed no significant difference between cancer
tissue samples and matched normal background tissue.
Using histologically normal appearing samples as the sole
control tissue is probably less appropriate. The use of
donor tissues (ideally obtained under similar conditions
as the tumor tissue) will serve as better controls. Donor
Figure 3 Detection of SOCS3 and SOCS7 in primary breast cancer 
samples by immunohistochemistry. Representative immunohis-
tochemistry staining of samples with low SOCS3 (A), high SOCS3 (B), 
low SOCS7 (C), and high SOCS7 (D). (×100)
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Page 12 of 13control, in addition to normal adjacent to tumors, pre-
cancerous lesions, and tumor samples will provide the
best sample set for resolution of genetic alterations that
are relevant to the disease process by minimizing the
potential implications of field cancerization. As there was
no normal donor tissue used in this study, it was not clear
whether the absence of a difference in SOCS expression
between tumour and matched normal background tissue
in our cohort was due to the effect of field cancerization.
Our data indicate that there may be a common signal-
ing mechanism controlling the various SOCS proteins
expression in breast cancer. Evidence from previous stud-
ies point to activated STAT5 as a possible SOCS2, SOCS3
and CIS genes controller and its loss may result in less
differentiated and more malignant tumours, and subse-
quently; poorer prognosis [21,48-51]. Similar mechanism
may well be existent for SOCS1 and SOCS4-7 gene con-
trol in breast cancer and this will need further investiga-
tion.
Our observations on the favorable role of SOCS protein
family in several clinico-pathological and prognostic
aspects of breast cancer have prompted us to perform
survival analysis to explore possible correlation of
SOCS1-7 proteins expression with disease-free survival
and overall survival in our cohort of breast cancer
patients.
After a median follow up period of 10 years, we found
higher levels of SOCS1, 2 and 7 expression among those
patients who remained disease-free compared to those
who developed local recurrence.
Similarly, we found higher levels of SOCS2, 4, and 7
expression in those who remained disease-free compared
to those who developed distant recurrence. Patients who
remained disease-free had higher levels of SOCS1 and 2
expression compared to those who died from breast can-
cer.
The disease free survival and overall survival curves
showed that higher levels of SOCS1, 3 and 7 were signifi-
cant predictors of better disease free survival and overall
survival. Higher levels of SOCS4 were significant in pre-
dicting better overall but not disease free survival.
Thus, in addition to the favorable positive correlation
between higher mRNA expression of several members of
the SOCS protein family and earlier more differentiated
breast cancer, we have also demonstrated a significant
positive correlation with patient's disease free and overall
survival over a relatively long median follow up period.
Conclusion
To our knowledge, this study is the first report to analyse
the expression of 7 members of the SOCS family and to
point to a favorable role of SOCS1, 3, 4, and 7 as predic-
tors of earlier tumour stage and better prognosis and clin-
ical outcome in breast cancer. Nevertheless, our
understanding of the molecular mechanisms involved in
the control of SOCS proteins expression and their regula-
tion by various cytokines in normal and malignant breast
tissue remains limited. Our data could be used in further
validation studies in order to establish a clear mechanism
of the JAK/STAT/SOCS interaction and its role in the
development and progress of breast cancer. Further
research should include correlations between SOCS
genes expression and the expression of other genes
related to apoptosis and proliferation.
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